Protective Action of Xymedon on the Morphological Structures of the Pancreas of the Rat in Ischemia
- 39 Downloads
Pathologic processes associated with the effect of ischemia on the pancreas are not yet fully investigated and searching for ways of reduction of the damaging effect of ischemia for providing full organ regeneration are of certain interest. Protective properties of xymedone with regard to pathologic processes in pancreas were studied on a model of total ischemia created by ligation of the coeliac and cranial mesenteric artery for 0 to 90 min. Pathologic structural changes in the pancreas in case of ischemia lasting up to 30 min are minor and therefore fully reversible. On the contrary, ischemia duration of more than 60 min in the group of animals not injected with xymedone can be seen as critical. We conclude that prior intraperitoneal injection of xymedone in the dose of 3.3 mg/kg helps to delay the development of pathologic processes in pancreatic parenchyma by approximately 30 min.
KeywordsIschemia Pancreas Pyrimidine derivative Xymedone
This study was supported by the Russian Government Program of Competitive Growth of Kazan Federal University and subsidy allocated to Kazan Federal University for the state assignment in the sphere of scientific activities.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflicts of interest.
- 1.Timoshin, А. А., Lakomkin, V. L., & Ruuge, E. К. (1998). Effect of a series of short cycles of ischemia and reperfusion on free-radical centres of rat isolated myocardial tissue. Biophysics, 43(1), 134–138.Google Scholar
- 2.Wehrli, F. W., Shaw, D., & Kneeland, J. B. (1988). Biomedical magnetic resonance imaging: principles, methodology and applications (p. 601). New York: VCH Publishers.Google Scholar
- 3.Kadyrov, R. К. (2012). Xymedone effect on destructive changes in pancreas caused by ischemia. Annals of Modern Clinical Medicine, 5(3), 14–17.Google Scholar
- 7.Malyshev, К. V. (2000). Xymedone antioxidant therapy in patients with chronic osteomyelitis. Annals of Surgery, 159(4), 59–63.Google Scholar
- 8.Cherepnev, G.V. (2002). Xymedone apoptosis-regulating activity. Author’s abstract of the post-doctoral thesis in Medicine, 44.Google Scholar
- 9.Izmailov, S. G., et al. (1999). Preclinical studies of Xymedone. Antibiotics and Chemotherapy, 8, 12–17.Google Scholar
- 10.Izmailov, G. А., Gorbunov, S. М., Izmailov, S. G., et al. (1998). Use of Xymedone in the treatment of thermal injury. Collection Topical Issues of Diagnosis and Treatment (Kazan), 52, 1998.Google Scholar
- 11.Cherepnev, G. V., Malyshev, К. V., Slabnov, Y. D., et al. (2000). Possible role of Xymedone antimutagenic effect in the modification of immune reactivity. Clinical Pharmacology and Therapy, 6, 79–81.Google Scholar
- 12.Slabnov, I. D., Vizel, А. А., & Cherepnev, G. V. (2000). Use of Xymedone as a systemic immunomodulatory agent in the setting of destructive pulmonary tuberculosis. Issues of Tuberculosis, 3, 28–32.Google Scholar
- 13.Izmailov, G. A., Yevranova, G. B., & Izmailov, S. G. (1993). Administration of Xymedone in the treatment of ischemic ulcers of lower extremities. Annals of Surgery, 151(7–12), 43–46.Google Scholar
- 14.Salikhov, I. G., Bodrova, R. А., & Ziganshina, L. Y. (2002). Xymedone-electrophoresis in rehabilitation of patients with systemic sclerosis. Issues of Balneology, Physical Therapy and Exercise Therapy, 5, 33–36.Google Scholar
- 15.Skorokhodkina, О. V., Tsibulkin, А. P., & Tsibulkina, V. N. (2004). Immunopharmacologic activity of Xymedone in patients with atopic asthma. Experimental Clinical Pharmacology, 67(5), 31–33.Google Scholar
- 16.Vlasov, A. P., Tarasova, Т. V., & Sudakova, G. N. (2000). Effect of antioxidants on intoxication in the setting of experimental peritonitis. Experimental Clinical Pharmacology, 63(6), 58–61.Google Scholar
- 17.Mosikhin, S. B., Tsiplakov, D. E., & Lopatin, А. S. (2006). Effect of Xymedone on the course of experimental sinusitis (immune histochemical study). Russian Rhinology, 1, 26–29.Google Scholar